Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Buprenorphine hydrochloride
Sandoz Ltd
N02AE01
Buprenorphine hydrochloride
400microgram
Sublingual tablet
Sublingual
Schedule 3 (CD No Register)
Valid as a prescribable product
BNF: 04070200; GTIN: 5050650092059
OBJECT 1 TEPHINE 400 MICROGRAM SUBLINGUAL TABLETS Summary of Product Characteristics Updated 27-Jan-2017 | Sandoz Limited 1. Name of the medicinal product Tephine 400 microgram Sublingual Tablets 2. Qualitative and quantitative composition Each tablet contains 400 microgramm of buprenorphine (as buprenorphine hydrochloride). Excipient: 44.8 mg lactose (as lactose monohydrate). For a full list of excipients, see section 6.1. 3. Pharmaceutical form Sublingual tablet. White to off white, round, biplane tablet with facet and one-sided ornamental notch (diameter: approximately 5.00 mm). The score line is not intended for breaking the tablet. 4. Clinical particulars 4.1 Therapeutic indications Tephine is used as astrong analgesic for the relief of severe pain, e.g. following surgery or injuries, myocardial infarction and in cancer. Use of Tephine is NOT indicated in the treatment of headache, toothache, migraine or other conditions involving pain which can be treated using peripherally active analgesics and/or spasmolytics. 4.2 Posology and method of administration _Dosage _ The dosage of Tephine should generally be adjusted to the intensity of the pain and the individual sensitivity of the patient. The recommended single dose in patients with a bodyweight greater than 45 kg is 1 sublingual tablet Tephine 400 microgram. The onset of effects generally occurs within 30 minutes after sublingual administration. The average duration of effects is 6 – 8 hours. If necessary, 1 sublingual tablet Tephine 400 microgram may be administered every 6 – 8 hours. In severe chronic pain, the dose of Tephine should be adjusted to the intensity of the pain and administered regularly in accordance with a fixed schedule corresponding to the duration of effects. Patients with a bodyweight of 35 – 45 kg should be given a single dose of 1 sublingual tablet Tephine 200 microgram, if necessary, every 6 – 8 hours. This is equivalent to an average single dose of 5 micrograms/kg bodyweight. Patients with a bodyweight of 16 – 35 kg should Read the complete document